Skip to main content

Table 2 The clinical application of combination of IP chemotherapy and systematic chemotherapy for gastric cancer patients with peritoneal metastasis

From: Issues on peritoneal metastasis of gastric cancer: an update

Authors
reference
Year Country Patients N IP
therapy
Systemic
therapy
MST
(m)
1-year
OS (%)
R0 resection (%)
Yamaguchi [51] 2013 Japan GC patients with PM 35 PTX PTX+S1 17.6 77.1 60.0
Kitayama [52] 2014 Japan GC patients with PM 64 PTX PTX+S1 26.4 82.0 53.1
Badgwell [57] 2017 USA GC patients with PM 19 HIPEC
MMC and CDDP
5-Fu+
oxaliplatin
30.2 94.7 26.3
Yonemura [6] 2017 Japan GC patients with PM 52 HIPEC
DTX and CDDP
DTX, CDDP and S1 19.2 - 57.6
  1. CDDP, cisplatin; DTX, docetaxel; HIPEC, hyperthermic intraperitoneal chemoperfusion; MMC, mitomycin C; PTX, paclitaxel